Mehraneh D. Jafari

Neoadjuvant Botensilimab/Balstilimab for localized mismatch repair proficient and deficient colon cancer: Results of the NEST phase 2 clinical trial

Manish A. Shah, Erika Hissong, Mehraneh D. Jafari, Pashtoon Murtaza Kasi et autres

PURPOSE: Effective immunotherapy for mismatch repair proficient colorectal cancer (CRC) is lacking. We examined the safety and efficacy of the novel next-generation immune activator/Fc-enhanced CTLA-4 inhibitor botensilimab (BOT) plus PD-1 inhibitor balstilimab (BAL) in the neoadjuvant setting for patients with resectable CRC. …

us, qa (code pays fourni par la source)

Transanal Total Mesorectal Excision and the Changing Role of Surgical Trials in Rectal Cancer Surgery

Mehraneh D. Jafari

us (code pays fourni par la source)

Immunotherapy Plus Surgery Improves Survival in Microsatellite Instability-High Colon Cancer with Isolated Peritoneal Metastases

Daniel Aryeh Metzger, Yasmeen Chahal, Olivia Watman, Ying Li et autres

Background: Microsatellite instability-high (MSI-H) colon cancer with isolated peritoneal metastases (iPM) represents a molecularly and anatomically distinct clinical subset with limited evidence to guide treatment. Given the unique immunogenic profile of MSI-H tumors and the historically poor prognosis of peritoneal dissemination, we …

us (code pays fourni par la source)

Intraperitoneal Chemotherapy: A Call to Study Reproductive Safety for Healthcare Workers

Princy Gupta, Elizabeth L. Godfrey, Kurt S. Schultz, Lumeng J. Yu et autres

us (code pays fourni par la source)

The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Appendiceal Neoplasms

Wolfgang B. Gaertner, Shaun R. Brown, Michael Deutsch, Mehraneh D. Jafari et autres

us (code pays fourni par la source)

ASO Visual Abstract: Genomic Signatures of Recurrence After Resection of Early-Stage Node-Negative Colon Cancer

Daniel Aryeh Metzger, Benjamin C. Greenspun, Julianna Brouwer, Ying Li et autres

us (code pays fourni par la source)

Urinary retention after laparoscopic low rectal cancer resection: post-hoc analysis of predictive factors in the GRECCAR 10 trial

Jean‐Luc Faucheron, Fatah Tidadini, Antoine Vilotitch, Alison Foote et autres

According to a recent literature review, the optimal duration of urinary drainage after rectal cancer surgery is unclear1, particularly for male patients. Early catheter removal probably reduces the risk of urinary tract infection2, but Lee et al.3 showed that urinary catheter removal …

fr (code pays fourni par la source)

ASO Author Reflections: Risk Stratification Using Genomic Data for Early-Stage Colon Cancer

Daniel Metzger, Benjamin C. Greenspun, Despina Siolas, Mehraneh D. Jafari

us (code pays fourni par la source)

Abstract PR005: Countering adenosine (ADO) in rectal cancer to improve RT responses to immune checkpoint blockade: a trial to test the safety and efficacy of PD1 (AB122) and ADO dual receptor (AB928) antagonists with chemotherapy after short-course RT

Encouse B. Golden, Sandra Demaria, Nir Ben Chetrit, Mehraneh D. Jafari et autres

Abstract Background: Rectal cancer (RC) is unresponsive to single agent immune checkpoint blockade (ICB), with the exception of microsatellite instability (MSI) high tumors. Neoadjuvant radiotherapy (RT), however, is a standard treatment for locally advanced RC. A recent analysis of RC showed that …

us (code pays fourni par la source)

Pouch outcomes after minimally invasive vs. open proctectomy during IPAA reconstruction

Daniel Aryeh Metzger, Andrea Mesiti, Josh Johnson, Ying Li et autres

us (code pays fourni par la source)

Genomic Signatures of Recurrence After Resection of Early-Stage Node-Negative Colon Cancer

Daniel Aryeh Metzger, Benjamin C. Greenspun, Julianna Brouwer, Ying Li et autres

us (code pays fourni par la source)

Immunotherapy for MSI-H colorectal cancer with isolated peritoneal metastases.

Daniel Aryeh Metzger, Olivia Watman, Ying Li, Alessio Pigazzi et autres

187 Background: NCCN guidelines recommend immunotherapy for MSI-H colon cancer (CC) with isolated peritoneal metastases (iPM); however, limited data support its benefit. This study aimed to evaluate the impact of immunotherapy in this population. Methods: Patients diagnosed with MSI-H CC with iPM …

us (code pays fourni par la source)